These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1675549)

  • 21. Neurohormonal and hemodynamic effects of ibopamine.
    Pouleur H
    Clin Cardiol; 1995 Mar; 18(3 Suppl I):I17-21. PubMed ID: 7743694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemodynamic effects of selective dopamine receptor agonists in the rat and dog.
    Hieble JP; Owen DA; Harvey CA; Blumberg AL; Valocik RE; DeMarinis RM
    Clin Exp Hypertens A; 1987; 9(5-6):889-912. PubMed ID: 2887313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopaminergic drugs in the management of chronic heart failure.
    Pouleur H; Raigoso J; Rousseau MF
    Eur Heart J; 1991 Aug; 12 Suppl C():29-34. PubMed ID: 1680685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
    Nichols AJ; Smith JM; Shebuski RJ; Ruffolo RR
    J Pharmacol Exp Ther; 1987 Aug; 242(2):573-8. PubMed ID: 2886644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemodynamic, renal, and neurohumoral effects of a selective oral DA1 receptor agonist (fenoldopam) in patients with congestive heart failure.
    Francis GS; Wilson BC; Rector TS
    Am Heart J; 1988 Aug; 116(2 Pt 1):473-9. PubMed ID: 2899970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine and dopamine receptor agonists in cardiovascular therapy.
    Murphy MB; Elliott WJ
    Crit Care Med; 1990 Jan; 18(1 Pt 2):S14-8. PubMed ID: 1967161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative significance of dopamine receptors, beta adrenoceptors and norepinephrine uptake inhibition in the cardiovascular actions of dopexamine hydrochloride.
    Goldberg LI; Bass AS
    Am J Cardiol; 1988 Aug; 62(5):37C-40C. PubMed ID: 2841837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat.
    Kerns WD; Arena E; Morgan DG
    Am J Pathol; 1989 Aug; 135(2):339-49. PubMed ID: 2571297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.
    Fitton A; Benfield P
    Drugs; 1990 Feb; 39(2):308-30. PubMed ID: 1970288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with intravenous fenoldopam.
    Holcslaw TL; Beck TR
    Am J Hypertens; 1990 Jun; 3(6 Pt 2):120S-125S. PubMed ID: 1974440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An introduction to the pharmacologic properties of Dopacard (dopexamine hydrochloride).
    Smith GW; O'Connor SE
    Am J Cardiol; 1988 Aug; 62(5):9C-17C. PubMed ID: 2900602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat.
    Kerns WD; Arena E; Macia RA; Bugelski PJ; Matthews WD; Morgan DG
    Toxicol Pathol; 1989; 17(1 Pt 2):203-13. PubMed ID: 2568682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of dopamine (DA) and SKF 82526, a selective DA1-receptor agonist, on vascular resistances in the canine forelimb.
    Grega GJ; Barrett RJ; Adamski SW; Lokhandwala MF
    J Pharmacol Exp Ther; 1984 Jun; 229(3):756-62. PubMed ID: 6144791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Studies on the pharmacological interventions to prevent oxygen free radical (OFR)-mediated toxicity; effects of dopexamine, a DA1 receptor and beta 2 adrenoceptor agonist.
    Jacinto SM; Lokhandwala MF; Jandhyala BS
    Naunyn Schmiedebergs Arch Pharmacol; 1994 Sep; 350(3):277-83. PubMed ID: 7824044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacology of ibopamine.
    Itoh H
    Am J Med; 1991 May; 90(5B):36S-42S. PubMed ID: 1675550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of ibopamine in the treatment of heart failure.
    Taylor SH; Cicchetti V
    Am Heart J; 1990 Dec; 120(6 Pt 2):1583-90. PubMed ID: 1978982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine: receptors and clinical applications.
    Goldberg LI
    Clin Physiol Biochem; 1985; 3(2-3):120-6. PubMed ID: 3159532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapeutic profile of ibopamine in heart failure.
    Taylor SH
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S118-23. PubMed ID: 2483437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased contribution of alpha 1- vs. beta-adrenoceptor-mediated inotropic response in rats with congestive heart failure.
    Sjaastad I; Schiander I; Sjetnan A; Qvigstad E; Bøkenes J; Sandnes D; Osnes JB; Sejersted OM; Skomedal T
    Acta Physiol Scand; 2003 Apr; 177(4):449-58. PubMed ID: 12648162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological bases for the use of dopamine and related drugs in the treatment of congestive heart failure.
    Goldberg LI
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S21-8. PubMed ID: 2483439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.